Cargando…

Morphological and Molecular Characterization of KRAS G12C-Mutated Lung Adenocarcinomas

SIMPLE SUMMARY: Lung adenocarcinoma is currently the main histological subtype of lung cancer, accounting for more than 60% of diagnosed cases. The most frequent genomic alteration in these tumors is the mutation of the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene, which until recently was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pirlog, Radu, Piton, Nicolas, Lamy, Aude, Guisier, Florian, Berindan-Neagoe, Ioana, Sabourin, Jean-Christophe, Marguet, Florent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870399/ https://www.ncbi.nlm.nih.gov/pubmed/35205778 http://dx.doi.org/10.3390/cancers14041030

Ejemplares similares

KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?
por: Piton, Nicolas, et al.
Publicado: (2015)

Assessment of endobronchial ultrasound‐guided bronchoscopy (EBUS) intranodal forceps biopsy added to EBUS 19‐gauge transbronchial needle aspiration: A blinded pathology panel analysis
por: Lachkar, Samy, et al.
Publicado: (2023)

HMGA2 immunostaining is a straightforward technique which helps to distinguish pulmonary fat-forming lesions from normal adipose tissue in small biopsies: a retrospective observational study about a series of 13 lung biopsies
por: Piton, Nicolas, et al.
Publicado: (2017)

Field Cancerization in NSCLC: A New Perspective on MicroRNAs in Macrophage Polarization
por: Pirlog, Radu, et al.
Publicado: (2021)

Cellular and Molecular Profiling of Tumor Microenvironment and Early-Stage Lung Cancer
por: Pirlog, Radu, et al.
Publicado: (2022)

The Roles of the Colon Cancer Associated Transcript 2 (CCAT2) Long Non-Coding RNA in Cancer: A Comprehensive Characterization of the Tumorigenic and Molecular Functions
por: Pirlog, Radu, et al.
Publicado: (2021)

The Glioblastoma CircularRNAome
por: Tirpe, Alexandru, et al.
Publicado: (2023)

Links between Infections, Lung Cancer, and the Immune System
por: Budisan, Liviuta, et al.
Publicado: (2021)

The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC
por: Rusu, Ioana, et al.
Publicado: (2022)

Melanoma Cellular Signaling Transduction Pathways Targeted by Polyphenols Action Mechanisms
por: Isacescu, Ecaterina, et al.
Publicado: (2023)

The Role of Non-Coding RNAs in Epigenetic Dysregulation in Glioblastoma Development
por: Isachesku, Ekaterina, et al.
Publicado: (2023)

The role of the pathology department in the preanalytical phase of molecular analyses
por: Susman, Sergiu, et al.
Publicado: (2018)

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
por: Bruera, Gemma, et al.
Publicado: (2013)

KRAS mutations as essential promoters of lymphangiogenesis via extracellular vesicles in pancreatic cancer
por: Pirlog, Radu, et al.
Publicado: (2022)

Identification of Potential microRNA Panels for Male Non-Small Cell Lung Cancer Identification Using Microarray Datasets and Bioinformatics Methods
por: Haranguș, Antonia, et al.
Publicado: (2022)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
por: Dantoing, Edouard, et al.
Publicado: (2021)

Assessing the feasibility of confocal laser endomicroscopy in solitary pulmonary nodules for different part of the lungs, using either 0.6 or 1.4 mm probes
por: Hassan, Tidi, et al.
Publicado: (2017)

Naproxen inhibits spontaneous lung adenocarcinoma formation in Kras(G12V) mice
por: Kumar, Gaurav, et al.
Publicado: (2021)

Spontaneous and Induced Animal Models for Cancer Research
por: Onaciu, Anca, et al.
Publicado: (2020)

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
por: Bournet, Barbara, et al.
Publicado: (2016)

Dual Inhibition of KRAS(G12D) and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
por: Gulay, Kevin Christian Montecillo, et al.
Publicado: (2023)

CRISPR/Cas9: A Potential Life-Saving Tool. What’s next?
por: Gulei, Diana, et al.
Publicado: (2017)

Combined Therapy in Cancer: The Non-coding Approach
por: Gulei, Diana, et al.
Publicado: (2018)

Activation of Necroptosis by Engineered Self Tumor-Derived Exosomes Loaded with CRISPR/Cas9
por: Gulei, Diana, et al.
Publicado: (2019)

Editorial: Women in cancer molecular targets and therapeutics, volume II: 2022
por: Berindan-Neagoe, Ioana, et al.
Publicado: (2023)

A case of Pseudomyxoma Peritonei of an unexpected origin
por: Csanyi-Bastien, Marie, et al.
Publicado: (2021)

Beyond the Frontline: A Triple-Line Approach of Thoracic Surgeons in Lung Cancer Management—State of the Art
por: Bottet, Benjamin, et al.
Publicado: (2023)

The Non-Coding RNA Journal Club: Highlights on Recent Papers—3
por: Berindan-Neagoe, Ioana, et al.
Publicado: (2015)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

Focal non granulomatous orchitis in a patient with Crohn’s disease
por: Piton, Nicolas, et al.
Publicado: (2015)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
por: Bruera, Gemma, et al.
Publicado: (2012)

Next-Generation Sequencing in Lung Cancer Patients: A Comparative Approach in NSCLC and SCLC Mutational Landscapes
por: Pop-Bica, Cecilia, et al.
Publicado: (2022)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases
por: Renaud, Stéphane, et al.
Publicado: (2015)

Combining the chemotherapeutic effects of epigallocatechin 3-gallate with siRNA-mediated p53 knock-down results in synergic pro-apoptotic effects
por: Berindan-Neagoe, Ioana, et al.
Publicado: (2012)

Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma
por: De Falco, Elena, et al.
Publicado: (2021)

In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy
por: Guisier, Florian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pmh2i5pmks1r4t00cthihahmij